1 / 36

Physiologically Based Pharmacokinetics – Lecture II

Physiologically Based Pharmacokinetics – Lecture II. Melvin Andersen CIIT Centers for Health Research October 27, 2006 University of North Carolina. TODAY’S TOPICS. PBPK Models for the Metabolism of Methylene Chloride and Application in Risk Assessment - Easy

aaron
Download Presentation

Physiologically Based Pharmacokinetics – Lecture II

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Physiologically Based Pharmacokinetics – Lecture II Melvin Andersen CIIT Centers for Health Research October 27, 2006 University of North Carolina

  2. TODAY’S TOPICS • PBPK Models for the Metabolism of Methylene Chloride and Application in Risk Assessment - Easy • Thinking about Pharmacokinetics while thinking more deeply about terms such as exposure and mixture? - Harder

  3. Metabolism of Inhaled Dihalomethanes In Vivo: • Two Pathways – How can we measure them?

  4. Gas Chromatograph 5 mL Gas Sampling Loop Stainless Steel Bellows Pump Particulate Filter O2 Monitor CO2 Scrubber INTEGRATOR Pressure Gauge Injection Port ~ 2.0 L/min ~ 100 mL/min Ice Filled Pan for H2O Condensation Desiccator Jar Chamber Experiments to Get Some of the Needed Parameters for a PBPK Model Gas Uptake and Metabolic Parameters Vial equilibration and Partitioning

  5. Tissue Partition Coefficients

  6. Chamber Volume Qalv Qalv Alveolar Space Calv (Cart/Pb) Cinh Qc Qc Lung Blood Cven Cart Qt Fat Tissue Group Cvt Cart Qm Muscle Tissue Group Cart Cvm Qr Richly Perfused Tissue Group Cart Cvr Liver Metabolizing Tissue Group Ql ( ) Cvl Cart Vmax Metabolites kf Km Adding a Different Exposure Scenario

  7. Gas Uptake Methods Estimate Metabolic Parameters: – Vmax and Km - kf Linear process Chamber loss with CH2BrCl Saturable process

  8. Motivation for Studying Bromide • We studied bromide concentrations in plasma after 4-hr exposures of rats to dibromomethane at various concentrations. • From data, determined production rates of bromide ion during exposure and thereby estimated biochemical constants (Vmax and Km and kfc) for metabolism of CH2Br2 or CH2BCl in rats. • Examine the effect of inducers and inhibitors on bromide production curves to see if we can discover the biochemical pathways of dihalomethane metabolism.

  9. kf Formation and Distribution of Bromide from Oxidation of Dibromomethane A complete distributional model for CH2Br2 with hepatic metabolism via Cytochrome P450 2E1 oxidation and GST.

  10. 2,3-EP reduces liver GSH • Pyrazole blocks microsomal oxidation Plasma inorganic bromide concentrations on ambient concentrations of CH2BrCl following 4-hr exposures using naive, 2,3-EP, and pyrazole-pretreated rats. The smooth curves were generated by the PBPK.

  11. What about carbon monoxide? HbCO concentrations in naïve, 2,3-EP-, and pyrazole-pretreated animals following 4-hr exposures to CH2BrCl.

  12. METHYLENE CHLORIDE - 1987 • Causes cancer in mouse lung and mouse liver by inhalation, but not in mice exposed via drinking water. • Metabolized by two pathways, each producing a reactive metabolite. Oxidation to formyl chloride and GST-conjugation to chloromethylglutathione • Either pathway could produce a mutagenic metabolite. Which is it?

  13. METHYLENE CHLORIDE - 1987 The two pathways contribute differentially at high and low exposure concentrations in rodents, as noted in studies with bromide release.

  14. METHYLENE CHLORIDE - 1987 • Responses related to intensity of tissue exposure to short-lived, spontaneously reactive intermediates. • Dose metric for PBPK modeling was estimated by • (amount metabolite formed )/tissue volume/time • Evaluate relationship between daily tissue exposure and cancer in the two-year mouse bioassay. • Provide an approach to extrapolate to lower doses, dose routes, and between mouse and humans.

  15. QP·CI QP·CX QC·CV QC·CA Lung Gas Exchange Lung Tissue MFO GST QR·CVR QR·CA Moderately Perfused Tissues Richly Perfused Tissues QM·CVM QM·CA Slowly Perfused Tissues QS·CVS QS·CA QF·CVF QF·CA GI Tract Fat QG·CA Drink QG·CVG (QL+QG)·CVL QL·CA Liver MFO GST PBPK Model Structure for Methylene Chloride Attributes: - Tissue Volumes - Blood Flows - Partition Coefficients - Metabolic Constants - Breathing Rate - Water Intake - Tissue metabolism

  16. Tissue Doses for CYP2E21 and GST Pathways of Metabolism

  17. Interspecies Dose Comparison for Metabolites from the Glutathione Transferase Pathway LIVER DOSE LUNG DOSE • The solid curve is calculated from the PBPK model for the mouse; the dashed curve is calculated for the human. The straight line is extrapolated based on a linear relationship, as was previously assumed. The difference between the upper and lower lines is about 70 to 80 fold.

  18. Using PBPK Models - 1987 Identify toxic effects in animals and/or people Evaluate available data on mode(s) of action, metabolism, chemistry of compound, metabolites and related chemicals Describe potential mode(s) of action Propose relation between response and tissue dose Develop a PBPK model to calculate tissue dose(s) Estimate tissue dose during toxic exposures with model Estimate risk in humans assuming similar tissue response for equivalent target tissue dose

  19. Develop PBPK parameters for CO portion of model in absence of DHM exposures. % HbCO Rats exposed to 500 ppm CO for 2 hr. What about carbon monoxide? Can we develop a PBPK model as well? Sure…

  20. Develop parameters for CO portion of PBPK model for humans. Human volunteers were exposed to 50, 100, 200, and 500 ppm CO (Stewart et al., 1975).

  21. Link DHM metabolism to CO production Human exposure to 50 and 350 ppm dichloromethane.

  22. Link DHM metabolism to CO production Human exposure to 50 and 350 ppm dichloromethane: time course of blood carboxyhemoglobin.

  23. What can we evaluate with a model of HbCO production from a Dihalomethane? • Metabolism to CO for methylene chloride first noted in a human volunteer study on carbon monoxide. • Volunteer doing paint stripping at home with solvents had high blood HBCO in the morning. • How could this happen?

  24. Experimental design in rat study !!! What’s going on here? Why do the compounds have different time courses? Blood carboxyhemoglobin levels after half-hour exposures to 5159 ppm dichloromethane or 5000 ppm bromochloromethane (BCM). Triangles are for BCM; circles are for DCM.

  25. Tissue Partition Coefficients

  26. II. Atrazine Metabolism & Inhibition in vitro Incubations conducted at 4 different atrazine concentrations for 90 min. All 4 chlorinated triazines were followed in the incubation media. What do you expect from a study of this kind? Ethyl Iso DACT McMullin, T.S. (2005). Integrating tissue dosimetry and mode of action to evaluate atrazine dose response. PhD Thesis, Colorado State University. In press at Toxicology in vitro

  27. Results with atrazine metabolism in rat hepatocytes look quite odd... What’s going on here? Any Ideas? 44 & 98 266 1.7

  28. Accounting for inhibition of metabolic pathways by multiple substrates RAMatra = (Vmaxatra*Catra) / (Catra + Katra*(1+Ciso/Kiso + Cethyl/Kethyl + Cdact/Kdact)) RAMatra = (Vmaxatra*Catra) / (Catra + Katra*(1+Ciso/Kiso + Cethyl/Kethyl + Cdact/Kdact)) Atrazine Isopropyl Ethyl DACT RAMiso = (Vmaxiso*Ciso) / (Ciso + Kiso*(1+ Cethyl/Kethyl + Catra/Katra + Cdact/Kdact)) RAMethyl=(Vmaxethyl*Cethyl)/ (Cethyl + KEthyl*(1+Catra/Katra+ Ciso/Kiso + Cdact/Kdact))

  29. Could it be competitive inhibition??? DACT dose-response at 90 minutes comparing model simulations (A) without and (B) with competitive metabolic inhibition terms. Lines represent model simulations. The non-linear behavior of DACT formation required a model that included competitive inhibition, where high [ATRA] inhibit further metabolism of Iso or Ethyl.

  30. Hexane (Hx) Exposures & Mixtures Hx induces changes in mean nerve conduction velocity. It is more potent at 1000 ppm than at 3000 ppm! What gives rise to this behavior?

  31. Hexane exposures produce 2,5-HD – the actual neurotoxicant. Blood concentrations of 2,5-HD are complexly related to inhaled Hx and have very unintuitive relationships over time. After cessation of Hx exposure in the 2 higher concentration groups, 2,5-HD actually increases over time. Where have you seen this behavior? Baker and Rikert (1979)

  32. Hexane PBPK Modeling CYP 2E1 Interactions arise from two primary sources: – competition for a common enzyme required for sequential steps in Hx oxidation - differential properties of Hx (low blood:air partitioning) versus m-n-BK (much higher blood:air partitioning) CYP 2E1 Clewell & Andersen (1984)

  33. Hexane Exposure Complex dose and time dependencies At higher Hx exposures, 2,5-HD increases after exposure cessation. Inhibitory interactions present during exposure are released as Hx is rapidly exhaled. Looks a lot like the atrazine story from the in vitro studies… Do you believe me? Do you want to buy a bridge? How could we test if this idea worked with other situations? - Clewell & Andersen (1984)

  34. Designer Mixture – A lipophilic compound (DBM) metabolized to CO and a poorly soluble anesthetic, isoflurane (ISO), in the air. What happens to CO? Develop a PBPK model with inhibition between ISO and DBM. Can you explain why you see the bump? What do we mean by exposure?

  35. You can be wrong! Air Metabolic Constants Tissue Solubility Tissue Volumes Blood and Air Flows Experimental System Lung Body Tissue Concentration X Fat X X X X X X Liver X Model Equations Time Define Realistic Model Make Predictions Collect Needed Data Refine Model Structure Physiologically Based Pharmacokinetic (PBPK) Modeling

More Related